The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

Serum Institute seeks alterations in clinical norms for Covid vaccine

Serum Institute seeks alterations in clinical norms for Covid vaccine
Serum Institute seeks alterations in clinical norms for Covid vaccine

Synopsis

Pune based Serum Institute of India (SII) that is conducting Phase 3 trial of the Oxford Covid-19 vaccine has approached India’s drug regulator seeking approval for changes to its protocol to broaden the horizon of the trials.

New Delhi: Pune based Serum Institute of India (SII) that is conducting Phase 3 trial of the Oxford Covid-19 vaccine has approached India’s drug regulator seeking approval for changes to its protocol to broaden the horizon of the trials by including people with health conditions and from different age groups in the trial. The company had presented its proposal for amendment in their clinical protocol on October 6. The matter was taken up by the
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

To Read the Full Story, Become an ET Prime Member

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Access the exclusive Economic Times stories, Editorial and Expert opinion

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times